January 29–February 02, 2023 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Francesco M. Marincola, Lisa H. Butterfield, David F. Stroncek, and Marcela V. Maus

-
Scientific Organizers: Francesco M. Marincola, Lisa H. Butterfield, David F. Stroncek, and Marcela V. Maus
Francesco M. Marincola
Lisa H. Butterfield
David F. Stroncek
Marcela V. Maus
***Meeting program subject to change.
Available Formats: = In Person = On DemandBooking Function
Fundraising
Merchandise Options
Registration Options
Sunday, January 29, 2023
Monday, January 30, 2023
Session Chair
CAR T Cells for Solid Tumors
Session Chair
CAR T Cells
Native T Cells for ACT
Novel CAR T Targets
T-Cell Therapy using Engineered TCRs
Session Chair
Enhancing Tumor Specificity of EGFR-targeting Therapies
Fully Synthetic TIL Enriched for Tumor Reactivity by Computational Prediction and High-Throughput TCR Synthesis
Generating a Universal T-Cell Therapy Using Covalent Immune Recruiters
Head-to-head Comparison of CD19 Directed Human CAR T and CAR NK Cells across CD28 and 4-1BB CAR Constructs
Improving Persistence and Efficacy of Cellular Therapies for Cancer through Glycolytic Reprogramming
In Depth Analyses of TIL Infusion Products and Correlations with Outcome of the Randomised Controlled Phase 3 Trial Comparing TIL to Anti-CTLA-4 in Advanced Melanoma
Session Chair
Mechanisms of Resistance to CAR T Cells in Hematologic Malignancies
Evaluating the Impact of CAR Design on the Tumor Immune Microenvironment and Anti-tumor Response in Syngeneic Glioma Model
Genome-wide CRISPR Activation and Interference Screens Discover Key Drivers of Primary Human T Cell Function
Tuesday, January 31, 2023
Session Chair
Synthetic Biology Approaches to Increase Specificity and Versatility
Inducible Programming of CAR T cell Function and Intrinsic Properties for Cancer Immunotherapy
Coopting T Cell Signaling Networks for Enhanced CAR T Cell Specificity and Efficacy
Short Talk: Short Talk: Controlling T-cell Signaling with Engineered Caffeine-induced Nanobodies
Short Talk: Short Talk: Engineered Human IL-2/IL-2Rb Orthogonal Pairs Selectively Enhance Anti-GPC3 CAR T Cells to Drive Complete Responses in Solid Epithelial Tumor Models
Short Talk: Short Talk: Novel Protease-mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances the Directionality of CAR-T cell Activity and Improves Target Cell Specificity
Short Talk: Short Talk: Real-Time Assessment of Engineered Immune Cell Potency, Persistence and Migration from Discovery to Process Development and Manufacturing
Session Chair
A Novel Autologous Tumor Model for the Study of Cellular Immunotherapy using Humanized Mice
CRISPR/Cas9-based Integration of a Large and Modular Cassette into a Safe Harbor Site to Improve CAR T Cell Therapy Efficacy and Safety
High-throughput Method to Analyze the Cytotoxicity of CAR T Cells in a 3D Tumor Spheroid Model using Image Cytometry
Large Knock-in in Primary T Cells with Optimized Cas9 HDR Methods and Design
MAD7-based Gene Editing Platform for Rapid and Efficient iPSC Engineering
Multi-Step Engineering of Gene-Edited CAR T Cells Using a Novel RNA Lipid Nanoparticle Reagent
Optimized Virus-free Manufacturing of Allogeneic CAR T Cells via CAR Targeting to the TRAC Locus using CRISPR/Cas9
Pin-pointTM Technology: A Versatile Base Editing Solution for the Generation of Cell Therapies
Session Chair
Modification of CAR Signaling Domain
Tracking and Characterizing Antigen-Specific T cells in Cancer Immunotherapy
Engineering Next-Generation CAR-T Cell Therapy for Cancer
Short Talk: Short Talk: Disruption of H3K9me3-mediated Gene Silencing Improves CAR T Cell Function
Short Talk: Short Talk: Harnessing CRISPR/Cas9 Mutagenesis Screening for Rational Design of Next-generation CAR-NKT Therapy against Neuroblastoma
Wednesday, February 1, 2023
Session Chair
Dead Cell Recognition in Immunity to Cancer
Regulation of NK Cell Activity is Solid Tumors
Two Cell Therapy Vignettes: Synapse Tuning and Targeting the ECM
Targeting Solid Malignancies With Patient-Derived ‘Public' Neoantigen TCRs
Evaluating the Therapeutic Potential of Natural Neoantigen-specific CD4+ T Cells
Associate Professor
Senior Principal Scientist
Editor-in-Chief
Session Chair
Towards the Development of Synthetic Immunity to Cancer
Engineering CAR Circuits
Valency-controlled Receptor for Inducible CAR T Control and Multiplexed T Cell Engineering
Short Talk: Short Talk: Engineering TCR-edited T Cells with Enhanced Antigen Reactivity to Target Solid Cancers Expressing the TP53 R175H Driver Mutation
Short Talk: Short Talk: Synthetic Cytokine Circuits Drive Targeted Infiltration and Proliferation of T Cells in Immune Excluded Tumors
Thursday, February 2, 2023
Session Chair
T-Cell Therapy using Neoantigen Reactive TCRs
Critical Aspects of DC Metabolism
CAR Macrophages for Solid Tumor Immunotherapy
Universal Redirection of Chimeric Antigen Receptor T Cells against Solid Tumors via Tumor Cell Membrane-inserting CAR Ligands
Short Talk: Short Talk: Identifying Novel Therapeutic Targets to Improve Adoptive Cell Therapy using a Model of Flt3L-mediated Tumor Suppression
Session Chair
Engineering Allogeneic CAR T Cells to Avoid GvHD and to Prevent Immune Rejection
Orthogonal Cytokine Engineering Drive Synthetic T Cell Effector States
Optimizing Engineered T Cell Manufacturing
Short Talk: Short Talk: Preclinical Characterization of CNTY-101, an Allogeneic iPSC-derived NK Product Candidate for the Treatment of B Cell Malignancies
Friday, February 3, 2023
Subscribe for Updates